001     169962
005     20240229133701.0
024 7 _ |a 10.3390/cancers13143451
|2 doi
024 7 _ |a pmid:34298664
|2 pmid
024 7 _ |a altmetric:109915568
|2 altmetric
037 _ _ |a DKFZ-2021-01662
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hau, Peter
|0 0000-0003-3894-5053
|b 0
245 _ _ |a Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23.
260 _ _ |a Basel
|c 2021
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1641137937_5855
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a adult
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a chemotherapy
|2 Other
650 _ 7 |a clinical trial
|2 Other
650 _ 7 |a magnetic resonance imaging
|2 Other
650 _ 7 |a medulloblastoma
|2 Other
650 _ 7 |a radiotherapy
|2 Other
650 _ 7 |a randomized
|2 Other
650 _ 7 |a subgrouping
|2 Other
650 _ 7 |a targeted therapy
|2 Other
700 1 _ |a Frappaz, Didier
|b 1
700 1 _ |a Hovey, Elizabeth
|0 0000-0002-9973-9360
|b 2
700 1 _ |a McCabe, Martin G
|0 0000-0002-5138-0707
|b 3
700 1 _ |a Pajtler, Kristian W
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 4
|u dkfz
700 1 _ |a Wiestler, Benedikt
|b 5
700 1 _ |a Seidel, Clemens
|b 6
700 1 _ |a Combs, Stephanie E
|b 7
700 1 _ |a Dirven, Linda
|b 8
700 1 _ |a Klein, Martin
|b 9
700 1 _ |a Anazodo, Antoinette
|0 0000-0002-5495-6062
|b 10
700 1 _ |a Hattingen, Elke
|0 0000-0002-8392-9004
|b 11
700 1 _ |a Hofer, Silvia
|b 12
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 13
|u dkfz
700 1 _ |a Zimmer, Claus
|b 14
700 1 _ |a Kortmann, Rolf-Dieter
|b 15
700 1 _ |a Sunyach, Marie-Pierre
|b 16
700 1 _ |a Tanguy, Ronan
|b 17
700 1 _ |a Effeney, Rachel
|b 18
700 1 _ |a von Deimling, Andreas
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Sahm, Felix
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Rutkowski, Stefan
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Berghoff, Anna S
|b 22
700 1 _ |a Franceschi, Enrico
|0 0000-0001-9332-4677
|b 23
700 1 _ |a Pineda, Estela
|0 0000-0003-2128-747X
|b 24
700 1 _ |a Beier, Dagmar
|0 0000-0002-3336-157X
|b 25
700 1 _ |a Peeters, Ellen
|b 26
700 1 _ |a Gorlia, Thierry
|b 27
700 1 _ |a Vanlancker, Maureen
|b 28
700 1 _ |a Bromberg, Jacoline E C
|b 29
700 1 _ |a Gautier, Julien
|b 30
700 1 _ |a Ziegler, David S
|0 0000-0001-7451-7916
|b 31
700 1 _ |a Preusser, Matthias
|b 32
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 33
|u dkfz
700 1 _ |a Weller, Michael
|0 0000-0002-1748-174X
|b 34
773 _ _ |a 10.3390/cancers13143451
|g Vol. 13, no. 14, p. 3451 -
|0 PERI:(DE-600)2527080-1
|n 14
|p 3451
|t Cancers
|v 13
|y 2021
|x 2072-6694
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169962
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2019
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-05-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2019
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21